Drug intelligence / Profile preview

PSX-002

Development stage: Preclinical
Lead developer: PsyRx
Modality: Small Molecules
Administration: Oral

Overview

PSX-002 is an ibogaine-based small molecule therapeutic under development by PsyRx for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related disorders. The drug is designed as a low-dose, once-daily oral formulation aimed at enhancing neuroplasticity and improving clinical outcomes while avoiding the hallucinogenic and cardiotoxic side effects typically associated with high-dose ibogaine. PSX-002 is currently in the discovery and preclinical stages of development.

Beyond the preview

Go deeper on PSX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSX-002.

Explore the full profile